Side effects of XXXX channel blockers.

@entity1671 @entity1296 @entity1 @entity712 @entity390 @entity101 @entity6 @entity4 @entity1855 @entity344 @entity3988 @entity460 @entity594 @entity10 @entity1142 @entity616
@entity460 channel blocking drugs are a chemically heterogenous group, so it might be expected that their effects on vascular smooth muscle, cardiac contractility, and conduction tissue may differ. However, the majority of adverse reactions are predictable from their pharmacological actions and may be conveniently grouped in the following categories: 1) vasodilatation, 2) negative inotropic effects, 3) conduction disturbances, 4) gastrointestinal effects, 5) metabolic effects, and 6) drug interactions. Vasodilatory symptoms, namely, @entity1296 , @entity10 , @entity1671 , and palpitation, are more likely with @entity594 . @entity4 is also common with @entity594 , but the mechanism is uncertain. For a given degree of vasodilation, the greatest negative inotropic effect is seen with @entity1855 first, @entity3988 second, and @entity594 last. @entity460 channel blocking drugs are contraindicated in @entity101 @entity1 with second and third degree @entity616 , and severe @entity712 . @entity1855 and @entity3988 have a significant effect on cardiac conduction, whereas @entity594 , in therapeutic doses, does not. @entity344 , such as @entity390 and @entity1142 , are common with @entity1855 . None of the @entity460 channel blocking drugs have been reported to adversely affect lipid or protein metabolism. However, @entity594 , @entity1855 , and @entity3988 in high doses may inhibit liberation of insulin. The significance of this finding needs to be explored further in @entity101 @entity6 . Serum digoxin levels have been shown to increase after administration of @entity1855 and @entity594 , but there is no evidence that this change has any clinical relevance.(ABSTRACT TRUNCATED AT 250 WORDS)
